Are critical normal gene products in cancer cells the real therapeutic targets?

Abstract excerpt

The majority of targets for rational anti-cancer drug development available at present have been defined by studies of early carcinogenesis. In this situation, mutations resulting in altered expression or structure of gene products, in the context of a relatively normal diploid background, provide the cell with a growth advantage. In contrast to cells studied in early carcinogenesis, however, profound chromosomal...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Division
• Share to Drug Design
• Share to Mutation